Skip to main
DCTH

Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems (DCTH) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Delcath Systems Inc. is focused on the treatment of primary and metastatic liver cancers through its innovative product, Melphalan Hydrochloride for Injection with the Delcath Hepatic Delivery System, which allows for high-dose chemotherapy specifically targeting the liver. The company's management is effectively expanding its treatment centers, anticipating positive results from the CHOPIN trial and the Medicaid National Drug Rebate Agreement (NDRA) program, contributing to the projected revenue growth despite lower overall forecasts, alongside improving margins that support profitability. Additionally, the expected adoption of Hepzato is bolstered by positive clinical data, a strategic increase in site activations, and initiatives aimed at enhancing referrals and reach into new geographic regions by 2025, fostering a strong outlook for continued growth through 2026.

Bears say

Delcath Systems Inc. reported a decline in preliminary total revenues for 3Q25, reaching $20.5 million, which represents a 15% quarter-over-quarter drop from $24.2 million in 2Q25 and falls below consensus estimates of $23.8 million. The company has revised its full-year revenue guidance for FY2025 down to $83 million to $85 million from a previous range of $93 million to $96 million, reflecting challenges such as decreased new site activations, reduced patient starts, and a decline in revenue per kit due to the Medicaid National Drug Rebate Agreement Program. Additionally, projected revenue for 2026 has been lowered significantly from $153.2 million to $107.6 million, indicating increasing uncertainty and unfavorable market conditions impacting Delcath's growth trajectory.

Delcath Systems (DCTH) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Delcath Systems (DCTH) Forecast

Analysts have given Delcath Systems (DCTH) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Delcath Systems (DCTH) has a Strong Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Delcath Systems (DCTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.